5-[5-Benzylsulfanyl-1-(3,5-dimethylphenyl)pyrazol-4-yl]-2-methyltetrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-[5-Benzylsulfanyl-1-(3,5-dimethylphenyl)pyrazol-4-yl]-2-methyltetrazole
• 英文别名: 5-[5-benzylsulfanyl-1-(3,5-dimethylphenyl)pyrazol-4-yl]-2-methyltetrazole
• 化学式: C₂₀H₂₀N₆S
• 分子量: 376.5
• InChiKey: QGLNGROLIBHLQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  86.7
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] SUBSTITUTUED PYRAZOLE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF.<br/>[FR] COMPOSÉS DE PYRAZOLE SUBSTITUÉS ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：RALLIS INDIA LTD

  公开号：WO2014002110A1

  公开（公告）日：2014-01-03

  The present disclosure provides a compound of formula I, its derivatives, salts, stereo-isomers, or regio-isomers thereof, useful as intermediates in preparation of sulfonamide or sulfonyl urea growth regulators or herbicides. Formula I The present disclosure further provides a process for preparing compound of formula I, its derivatives, salts, stereo-isomers, or regio-isomers thereof.

  本公开提供了一种公式I的化合物，以及其衍生物、盐、立体异构体或位置异构体，可用作磺胺类或磺酰脲生长调节剂或除草剂的中间体。公式I。本公开还提供了一种制备公式I的化合物，以及其衍生物、盐、立体异构体或位置异构体的方法。
• METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF
  申请人：Del Mar Pharmaceuticals

  公开号：EP2872161A2

  公开（公告）日：2015-05-20
• [EN] METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF<br/>[FR] MÉTHODES DE TRAITEMENT DE MALIGNITÉS RÉSISTANTES À UN INHIBITEUR DE TYROSINE KINASE CHEZ DES PATIENTS AYANT DES POLYMORPHISMES GÉNÉTIQUES OU DES DÉRÉGULATIONS OU DES MUTATIONS D'AHI1 À L'AIDE DE DIANHYDROGALACTITOL, DIACÉTYLDIANHYDROGALACTITOL, DIBROMODULCITOL OU DES ANALOGUES OU DÉRIVÉS CORRESPONDANTS
  申请人：DEL MAR PHARMACEUTICALS

  公开号：WO2014004376A2

  公开（公告）日：2014-01-03

  Methods and compositions suitable for the treatment of malignancies in subjects with a germline deletion polymorphism that blocks the activity of thymidine kinase inhibitors in triggering apoptosis in tumor cells or in subjects having a mutation in or a dysregulation of the AHI1 gene are disclosed. These methods employ an alkylating hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative or analog of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative or analog of dibromodulcitol. The compositions can include such alkylating hexitol derivatives. The methods can further include administration of a BH3 mimetic, and the compositions can further include a BH3 mimetic. In subjects having a dysregulation of the AHI1 gene, the methods can further include the administration of an agent modulating the expression or activity of the AHI1 gene or AHI1 protein, and the compositions can further include such an agent.